Top 10 Articles
Top Article: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Abstract
Background: Bapineuzumab, a humanized anti-amyloid-beta (A) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.
Methods: The study enrolled 234 patients, randomly… Continue Reading
Methods: The study enrolled 234 patients, randomly… Continue Reading